Hematology

Top Story

Top Takeaways from ASH: Benefits, drawbacks of Factor VIII products require discussion with patients

Top Takeaways from ASH: Benefits, drawbacks of Factor VIII products require discussion with patients
May 26, 2016

The multicenter, randomized Survey of Inhibitors in Plasma-Product Exposed Toddlers, or SIPPET study, presented at the ASH Annual Meeting and Exposition, which demonstrated that recombinant Factor VIII products may lead to a 1.87-fold increased risk for the development of an inhibitor compared with plasma-derived products among patients with severe hemophilia A, represents “significant” results that impact the therapeutic choices made about the different Factor VIII products.

“This is quite a significant finding. Inhibitors are a very serious problem for patients with hemophilia,” according to Ulrike M. Reiss, MD, associate faculty member and director of clinical hematology and the hemophilia treatment center at St. Jude Children’s Research Hospital. “They basically neutralize any infused factor and, therefore, there is no optimal way of treating, and stopping, bleeding.”

FDA News

FDA approves Afstyla to treat patients with hemophilia A

May 26, 2016
The FDA approved antihemophilic factor (recombinant), single chain to treat adults and children with hemophilia A.Antihemophilic factor (recombinant), single chain…
In the Journals

Catheter-directed thrombolysis reduces post-thrombotic syndrome after DVT

May 26, 2016
Catheter-directed thrombolysis appeared associated with a persistent risk reduction for post-thrombotic syndrome among patients with extensive proximal deep vein…
In the Journals

Emicizumab reduces bleeding in patients with severe hemophilia A

May 25, 2016
Weekly subcutaneous administration of the bispecific antibody emicizumab decreased the rate of bleeding events in patients with hemophilia A, according to the results of…
CME

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Video
At Issue

VIDEO: Adoptive T-cell therapy poised to become ‘mainstay’ in myeloma treatment paradigm

February 16, 2016
More »
Featured
AACR Annual Meeting

AACR Annual Meeting

CME

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease…
More »
Meeting News Coverage

Top Takeaways from ASH: Benefits, drawbacks of Factor VIII products require discussion with patients

May 26, 2016
The multicenter, randomized Survey of Inhibitors in Plasma-Product Exposed Toddlers, or SIPPET study, presented at the ASH Annual Meeting and…

FDA News

FDA approves Afstyla to treat patients with hemophilia A

May 26, 2016
The FDA approved antihemophilic factor (recombinant), single chain to treat adults and children with hemophilia A.Antihemophilic factor…

In the Journals

Catheter-directed thrombolysis reduces post-thrombotic syndrome after DVT

May 26, 2016
Catheter-directed thrombolysis appeared associated with a persistent risk reduction for post-thrombotic syndrome among patients with extensive…

In the Journals

Emicizumab reduces bleeding in patients with severe hemophilia A

May 25, 2016
Weekly subcutaneous administration of the bispecific antibody emicizumab decreased the rate of bleeding events in patients with hemophilia A…

Five treatment advances for children with sickle cell disease

May 25, 2016
Patients with sickle cell disease show signs of disease during the first year of life.Symptoms and complications are different for each person…

In the Journals

Prasugrel fails to ease vaso-occlusion burden in sickle cell disease

May 24, 2016
Treatment with prasugrel did not significantly reduce the rate of vaso-occlusive crisis in children and adolescents with sickle cell anemia…

Meeting News Coverage

Top Takeaways from ASH: Oral anticoagulants shift cancer-related thrombosis treatment paradigm

May 24, 2016
With a range of questions lingering unanswered in the arena of cancer-related thrombosis, new research presented at the ASH Annual Meeting and…

In the Journals

Select patients with sickle cell anemia can safely stop transfusions

May 23, 2016
Children with sickle cell anemia and normalized transcranial Doppler velocities on transfusions appeared able to safely switch to hydroxyurea with…

At IssueVideo

VIDEO: Wide array of therapeutic options in myeloma a ‘wonderful problem’ for hematologists

May 19, 2016
Adriana Rossi, MD, of the Multiple Myeloma Center at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York, discusses the…

Meeting News Coverage

Hydroxyurea therapy improves lung function in children with sickle cell disease

May 18, 2016
Hydroxyurea therapy decreased the rate of annual decline in pulmonary function among children and young adults with sickle cell disease, according to…

More Headlines »
morganatic-roan